Rekombinanter ITGAL (Efalizumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter ITGAL (Efalizumab Biosimilar) Antikörper (ABIN7795106)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Efalizumab Biosimilar, CD11a Monoclonal Antibody
-
Produktmerkmale
- Efalizumab Biosimilar uses the same protein sequences as the therapeutic antibody efalizumab. Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human CD11a
-
-
anti-ITGAL (Efalizumab Biosimilar) antibody
Reaktivität: Human FACS, BR Wirt: Kaninchen Chimeric hu1124 unconjugated Recombinant Antibody
anti-ITGAL (Efalizumab Biosimilar) antibodyReaktivität: Human FACS, BR Wirt: Human Monoclonal hu1124 unconjugated Recombinant Antibody
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- ITGAL (Efalizumab Biosimilar)
-
Andere Bezeichnung
- Efalizumab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-
